1. Reduced expression of erythropoietin-producing hepatocyte B6 receptor tyrosine kinase in prostate cancer
- Author
-
Esam Salem, Elnisr Rashed Mohamed, Kyogo Itoh, Ahmed Hamed, Masanori Noguchi, Mohamed Zaki Eldahshoury, and Ahmed Hammady
- Subjects
PCA3 ,Cancer Research ,Pathology ,medicine.medical_specialty ,Tissue microarray ,Oncogene ,biology ,business.industry ,Prostatectomy ,medicine.medical_treatment ,Cancer ,Articles ,medicine.disease ,prostate cancer ,cancer volume ,Receptor tyrosine kinase ,Prostate cancer ,Oncology ,erythropoietin-producing hepatocyte B6 expression ,biochemical progression-free survival ,biology.protein ,receptor tyrosine kinase ,Medicine ,Immunohistochemistry ,business - Abstract
Loss of erythropoietin-producing hepatocyte (Eph) B6 gene expression is associated with poor prognosis in neuroblastoma, melanoma and other tumors. The present study evaluated the expression of EphB6 receptor tyrosine kinase in normal and prostate cancer tissue using immunohistochemistry. The association between EphB6 expression, clinicopathological findings, proliferating-cell nuclear antigen (PCNA; another prognostic marker) and progression of prostate cancer was analyzed. Tissue microarray samples of normal prostatic tissue and prostate cancer tissue from 46 patients treated with radical prostatectomy for prostate cancer were included in this study. Polyclonal anti-EphB6 and monoclonal anti-PCNA antibodies were used to assess EphB6 and PCNA expression by immunohistochemistry. EphB6 was expressed in normal and prostate cancer tissue; however, its expression was significantly reduced in prostate cancer tissue compared with normal prostatic tissue (P
- Published
- 2014